Cantor Fitzgerald initiates Healthpeak Properties stock with Neutral rating

Cantor Fitzgerald initiated Healthpeak Properties (DOC) with a Neutral rating and a $20.00 price target, citing a high 81.3x P/E and limited life science exposure despite potential in the biotech sector and a strong balance sheet. This cautious stance contrasts with Raymond James' upgrade to Outperform and Mizuho's maintained Outperform (albeit with lowered FFO estimates), while KeyBanc reiterated Sector Weight due to ongoing lab occupancy concerns. Concurrently, Healthpeak priced a $500 million public offering of 4.750% senior unsecured notes due 2033, securing approximately $492.8 million in net proceeds.

Analysis

Healthpeak Properties (DOC) presents a mixed investment profile characterized by divergent analyst ratings and recent capital markets activity. Cantor Fitzgerald's initiation with a Neutral rating and a $20.00 price target is anchored in a valuation framework that appears conservative, using a 2026 estimated AFFO multiple of 12.8x, well below the 19.0x REIT industry average. This cautious stance is taken despite acknowledging a strong balance sheet and future potential from a rebound in the biotech sector, which impacts its 35% Life Science portfolio. This contrasts sharply with Raymond James' upgrade to Outperform on valuation grounds, and Mizuho's maintained Outperform rating, although the latter trimmed FFO estimates. Further tempering enthusiasm is KeyBanc's Sector Weight rating, which cites persistent concerns over lab occupancy. Concurrently, the company has bolstered its liquidity by pricing a $500 million public offering of senior unsecured notes due 2033 at a 4.750% interest rate, generating net proceeds of approximately $492.8 million. This activity, combined with the high P/E ratio of 81.3x, positions the stock at a crossroads where its stable Medical Office majority and balance sheet strength are weighed against specific operational headwinds and a rich valuation.

Key Decisions for Investors

• Investors should weigh the conflicting analyst rationales, contrasting the valuation-based optimism from Raymond James with the operational concerns over lab occupancy highlighted by KeyBanc.
• Given the elevated 81.3x P/E ratio, it is critical to assess whether the long-term growth catalyst from the Life Science portfolio justifies the current premium or if the valuation presents a near-term risk.
• Monitor the company's leverage profile following the $500 million debt issuance and watch for improvements in lab occupancy rates as a key indicator for validating the more optimistic outlooks.